Unknown

Dataset Information

0

IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma.


ABSTRACT: The cytokine IL-12 induces IFN-? production by T and NK cells. In preclinical models, it contributes to antitumor immunity. However, in clinical testing, it has shown limited benefit in patients with any one of a variety of malignancies. Moreover, in a clinical trial testing a combination of IL-12 and rituximab in patients with follicular B cell non-Hodgkin lymphoma (FL), those treated with IL-12 showed a lower response rate, suggesting that IL-12 actually plays a detrimental role. Here, we investigated whether the failure of IL-12 treatment for FL was due to T cell exhaustion, a condition characterized by reduced T cell differentiation, proliferation, and function, which has been observed in chronic viral infection. We found that extended exposure to IL-12 induced T cell exhaustion and contributed to the poor prognosis in FL patients. Long-term exposure of freshly isolated human CD4+ T cells to IL-12 in vitro caused T cell dysfunction and induced expression of TIM-3, a T cell immunoglobulin and mucin domain protein with a known role in T cell exhaustion, via an IFN-?-independent mechanism. TIM-3 was required for the negative effect of IL-12 on T cell function. Importantly, TIM-3 also was highly expressed on intratumoral T cells that displayed marked functional impairment. Our findings identify IL-12- and TIM-3-mediated exhaustion of T cells as a mechanism for poor clinical outcome when IL-12 is administered to FL patients.

SUBMITTER: Yang ZZ 

PROVIDER: S-EPMC3314462 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma.

Yang Zhi-Zhang ZZ   Grote Deanna M DM   Ziesmer Steven C SC   Niki Toshiro T   Hirashima Mitsuomi M   Novak Anne J AJ   Witzig Thomas E TE   Ansell Stephen M SM  

The Journal of clinical investigation 20120319 4


The cytokine IL-12 induces IFN-γ production by T and NK cells. In preclinical models, it contributes to antitumor immunity. However, in clinical testing, it has shown limited benefit in patients with any one of a variety of malignancies. Moreover, in a clinical trial testing a combination of IL-12 and rituximab in patients with follicular B cell non-Hodgkin lymphoma (FL), those treated with IL-12 showed a lower response rate, suggesting that IL-12 actually plays a detrimental role. Here, we inve  ...[more]

Similar Datasets

| S-EPMC4145058 | biostudies-literature
| S-EPMC3477524 | biostudies-literature
| S-EPMC8803106 | biostudies-literature
| S-EPMC10651334 | biostudies-literature
| S-EPMC6936234 | biostudies-literature
| S-EPMC5671557 | biostudies-literature
| S-EPMC3102652 | biostudies-literature
| S-EPMC3317889 | biostudies-literature
| S-EPMC9189347 | biostudies-literature
| S-EPMC3637013 | biostudies-literature